SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine

Dan Williams and Amy Sheridan-Hill, whose son Frankie suffers from H-ABC, interviewed for the Evening Standard.

Dan Williams interviewed for leading podcast, Beyond Biotech

In a major article, Dan Williams considers how to overcome obstacles in rare disease treatment

Leading biotech appoints senior industry figure as Chief Medical Officer to define clinical strategy and oversee trials

Bioscience Today features major Dan Williams article about collaboration driving rare disease drug development

Dan Williams says Big Pharma could help accelerate market introduction for rare disease drugs

SynaptixBio awarded second FDA Orphan Drug Designation to boost search for rare disease therapies

BBC features TUBB4A leukodystrophy case study – Dan Williams contribution highlights lack of widespread awareness of rare diseases

Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story

Leading biotech firm welcomes new NHS rapid diagnostic service for rare diseases, but says wider newborn screening is key

SynaptixBio awarded prestigious Innovate UK grant to expand search for rare disease therapies

Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease.

British biotech firm secures FDA rare paediatric disease designation

Children with undiagnosed conditions urged to get checked for rare, incurable and deadly disease